Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying
Cycle design and robustness testing using advanced process analytical technology.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 88-93

where ΔH s is the heat of sublimation of ice (670 cal/g used as constant), P ice is the vapor pressure of ice (Torr, known from the first experiment), P c is the chamber pressure (Torr), R p and Rs are the product and stopper resistance, respectively (cm2 Torr h/g, known from the first experiment), A v is the vial outer cross-sectional area (6.83 cm2), K v is the vial heat transfer coefficient (104 cal/sec cm2 K, cf.) (see Table I), T s is the shelf-inlet temperature (C) and Tb the temperature at the bottom of the vial (C).


Table I: Summary of process conditions for 50–200 mg/mL sucrose solutions and corresponding maximum product temperature data (Tp-max) during primary drying.
Table I illustrates the theoretical values obtained from the steady-state model for the maximum product temperature (T p-max ) when using a 5 C shelf temperature variation at constant pressure (62 mTorr) or an increase in chamber pressure from 62 to 200 mTorr at constant T s .


Figure 4
The modeled results obtained for T p-max were found in fairly good agreement to the experimental data. Note that this observation has been reported in the literature (11). However, the effect of T s and P c on product temperature was lower in the experiments performed relative to the theoretical calculations, in particular for applied pressure changes. Although such simulation is useful for scale-up, rational design of the freeze-drying process and troubleshooting, simulations cannot eliminate the need for careful experimentation (12).


Figure 5
Product resistance. Rp data determined for products dried by the optimized cycle increased almost linearly over Ldry, indicating an absence of shrinkage and microcollapse (see Figure 4) (4, 5). The variation of T s by 5C showed no clear impact on R p. However, the pressure increase up to 200 mTorr resulted in a significant decrease in R p over L dry. Microcollapse as well as shrinkage in these products could be detected visually and by SEM (see Figure 5b).

Note that an increase in solute concentration led to a similar R p curve shape relative to the samples at high P c, but the product matrix revealed much greater robustness to elevated temperature (see Figures 4 and 5c). This observation was in excellent agreement with the T c difference measured by FDM between 50 mg/mL (T c= –34 C) and 200 mg/mL (T c = –32 C) sucrose solutions. Note that the dependency of sucrose concentration on T c was recently investigated but is in contrast to data obtained in early studies on a different amorphous system (8, 13).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here